Trial Profile
Prostvac in Patients With Biochemically Recurrent Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Nov 2022
Price :
$35
*
At a glance
- Drugs Rilimogene galvacirepvec-rilimogene glafolivec (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 10 Nov 2022 Status changed from active, no longer recruiting to completed.
- 26 Sep 2020 Planned End Date changed from 1 Oct 2021 to 1 Oct 2022.
- 21 Sep 2020 Results (n=71) assessing change in PSA DT and PSA declines compared to surveillance in subset of biochemically recurrent prostate cancer patients presented at the 45th European Society for Medical Oncology Congress